BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 11895880)

  • 21. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced transcription of the RB2/p130 gene in human lung cancer.
    Xue Jun H; Gemma A; Hosoya Y; Matsuda K; Nara M; Hosomi Y; Okano T; Kurimoto F; Seike M; Takenaka K; Yoshimura A; Toyota M; Kudoh S
    Mol Carcinog; 2003 Nov; 38(3):124-9. PubMed ID: 14587097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.
    Walter K; Holcomb T; Januario T; Du P; Evangelista M; Kartha N; Iniguez L; Soriano R; Huw L; Stern H; Modrusan Z; Seshagiri S; Hampton GM; Amler LC; Bourgon R; Yauch RL; Shames DS
    Clin Cancer Res; 2012 Apr; 18(8):2360-73. PubMed ID: 22261801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
    Kang GH; Lee S; Lee HJ; Hwang KS
    J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
    Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
    Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer.
    Liu Z; Zhao J; Chen XF; Li W; Liu R; Lei Z; Liu X; Peng X; Xu K; Chen J; Liu H; Zhou QH; Zhang HT
    Lung Cancer; 2008 Oct; 62(1):15-22. PubMed ID: 18358560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
    Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
    Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
    Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypermethylation in histologically distinct classes of breast cancer.
    Bae YK; Brown A; Garrett E; Bornman D; Fackler MJ; Sukumar S; Herman JG; Gabrielson E
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5998-6005. PubMed ID: 15447983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
    Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
    Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays.
    Wikman H; Seppänen JK; Sarhadi VK; Kettunen E; Salmenkivi K; Kuosma E; Vainio-Siukola K; Nagy B; Karjalainen A; Sioris T; Salo J; Hollmén J; Knuutila S; Anttila S
    J Pathol; 2004 May; 203(1):584-93. PubMed ID: 15095482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients.
    Son JW; Jeong KJ; Jean WS; Park SY; Jheon S; Cho HM; Park CG; Lee HY; Kang J
    Cancer Lett; 2011 Dec; 311(1):29-37. PubMed ID: 21757291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CpG island methylation and expression of tumour-associated genes in lung carcinoma.
    Dammann R; Strunnikova M; Schagdarsurengin U; Rastetter M; Papritz M; Hattenhorst UE; Hofmann HS; Silber RE; Burdach S; Hansen G
    Eur J Cancer; 2005 May; 41(8):1223-36. PubMed ID: 15911247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5' CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC.
    Qiu G; Fang J; He Y
    Clin Biochem; 2006 Mar; 39(3):259-66. PubMed ID: 16516880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
    Sugita M; Geraci M; Gao B; Powell RL; Hirsch FR; Johnson G; Lapadat R; Gabrielson E; Bremnes R; Bunn PA; Franklin WA
    Cancer Res; 2002 Jul; 62(14):3971-9. PubMed ID: 12124329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus.
    Chang MS; Uozaki H; Chong JM; Ushiku T; Sakuma K; Ishikawa S; Hino R; Barua RR; Iwasaki Y; Arai K; Fujii H; Nagai H; Fukayama M
    Clin Cancer Res; 2006 May; 12(10):2995-3002. PubMed ID: 16707594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
    Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
    Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.